The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Meanwhile, his is the company, Inflazome, co-founded by POLB NED Luke O'Neill, where POLB CEO Skillington was Business Development Head.
hxxp://www.inflazome.com/press-release-21-sep-2020.html
I like : .."Inflazome shareholders received €380 million upfront, and are eligible to receive additional milestone payments..,
especially given that .."The Company, which was established just four years ago, developed a portfolio of clinical and pre-clinical molecules with a lean, highly experienced team and limited invested capital.”
The portfolio is pretty early stage stuff, maybe even less advanced than POLB, see
".. a portfolio of orally available small molecule NLRP3 inhibitors, with lead molecules having successfully completed Phase I clinical trials, as well as several high potential earlier-stage programmes..."
The limited investment capital was .." €55m in Venture Capital financing from leading investors Forbion, Longitude Capital, Fountain Healthcare Partners and Novartis Venture Fund..."
I haven't seen what %age of the shares the VC companies got for their Euro 55m, but even if it was the lion's share, the founder investors probably did OK.
And they'll have fronted some cash, unlike you and me.
AIUI
If not seen, this is a good summary - Poolbeg's 'pitch' , including profiles, business plan , IP description , USP, market etc :
https://www.investegate.co.uk/poolbeg-pharma-plc/rns/intention-to-float-on-aim/202106170700161710C/
Skillington, the CEO reports to a BoD including a NED , Luke O'Neill, who co-founded in 2016 the business that was sold off to Roche last year for Euro 380m.
The other NEDs aren't too shabby, either ;->
Indeed, Ivy. The Prof. has some impressive credentials including being a FRS.
https://www.marathi.tv/personalities/prof-luke-o-neil/
Recent press coverage.
https://www.irishtimes.com/business/health-pharma/open-orphan-spin-out-poolbeg-pharma-to-list-on-london-market-1.4595948
And most important link, to his band. :)
https://www.facebook.com/TheMetabollix/
Morning,
Lots of good info starting to come out about Poolbeg spin off and think this is going to be much bigger than simply monetising a bottom drawer non core asset.Look st background off Jeff Skillington and Prof Luke O Neil who will be in Poolbeg Scientific Board.
Looking at a 20m raise.
Evening,
Earache we have different perspectives of how we saw the Thursday presentation as I thought it was good and was happy with the detail.That is fine.
Let us say relook at our positions in a months time.
So CF said material news so I am thinking a big contract in order of £10m and then he will buy a lot of shares and we will see Poolbeg IPO
We can park the rest of the stuff but if there is a said contract and he does buy substantial amounts and Poolbeg lists as planned then I feel vindicated.
If there is no material news,he does not buy lots of shares etc then I will concede you have probably judged the situation better than me.
So let us just see how the next 3-4 weeks plays out
ATB
Earache - you not happy with progress in last 18 months? You sold and trying to get back cheaper? You don't think it's gonna be very good from here in 18 months time?
Thanks everyone that's replied, its interesting and helpful to hear other points of view. I'm staying in, as I've said before, and I think it'll be an interesting time ahead. GLA.
charlie - I understand what you're saying. for me its not about trying to second guess exactly when things are going to happen, or precise short term valuations as each spin-off occurs or dissection of CF's every utterance. Where do you think total valuation will be in 18 months / 2 years? I reckon at least 3x current level, all-in. Which I'll be very happy with.
But actually I doubt very much whether core ORPH will be here by then. I fully expect it to be bought out, possibly even during 2021 once arrangements are in place for all spin offs. In my view the longer a suitor for core ORPH waits the more they're going to have to pay for it - as the businesses become further established, growing customer base, contracts won, facilities expand, new products and services launched, profitability becomes larger and clearer etc etc - so I'm expecting something sooner rather than later, and I trust CF to negotiate a good deal.
Partly because CF does guide the market, this stock is traded a lot. V liquid. I wouldnt be concerned if you are underwater, CS. CF has delivered throughout. If no rns on monday, might be slight pullback but dips will be bought up and stronger as the week goes on. Market overreacted to the final results. It was obvious the results were not go8ng to be great. CF even said so himself in the presentation a few weeks ago
Partly because CF does guide the market, this stock is traded a lot. V liquid. I wouldnt be concerned if you are underwater, CS. CF has delivered throughout. If no rns on monday, might be slight pullback but dips will be bought up and stronger as the week goes on. Market overreacted to the final results. It was obvious the results were not go8ng to be great. CF even said so himself in the presentation a few weeks ago
Wondergoals, depends when you got in and at what average as to how people may react. I am happy for long term holders with low averages, but I've been mostly spiked since March on a 36p average and the goal posts have moved a fair amount this week.
For example, no-one has yet talked about the DIM spin out being brought forward, which changes the way I am perceiving the momentum of the share price to December. Now the DIM spin out might play out during the release of the H1 21 provisional results and I am wary of it replicating this week in terms of sentiment.
The 'DIM carrot' was set for late Autumn, which along with the idea of OO being eventually sold off, was quite an attractive sentiment for new and old investors to hold much longer than a lot of AIM investors do. I was hoping there was share price stability in that trajectory.
Things have changed somewhat, despite people saying they haven't. What impact that has remains to be seen, but it certainly makes it trickier for me to read where I think the share price is going and whether I might be underwater again after DIM.
Sell price was ticking up on every sale today, someone is accumulating and it can't be Cathal yet
so much whining and questioning company and management after a very good presentation yesterday eve, investor questions answered, 10% rise in sp today, we're leaders in multiple fields with dynamic and committed leadership, great communication, cash generating and profitable, clear plan to deliver exceptional shareholder value and everything going for us looking forward. what's wrong with you people?